{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:18:34Z","timestamp":1789730314321,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011919","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000}}],"reference-count":116,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011919.pub2","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:11:16Z","timestamp":1579900276000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Resveratrol for adults with type 2 diabetes mellitus"],"prefix":"10.1002","volume":"2020","author":[{"given":"Maya M","family":"Jeyaraman","sequence":"first","affiliation":[{"name":"University of Manitoba; Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation; Winnipeg MB Canada R3A 1R9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nameer S H","family":"Al-Yousif","sequence":"additional","affiliation":[{"name":"University of Manitoba; Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation; Winnipeg MB Canada R3A 1R9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrinder","family":"Singh Mann","sequence":"additional","affiliation":[{"name":"University of Manitoba; Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation; Winnipeg MB Canada R3A 1R9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon W","family":"Dolinsky","sequence":"additional","affiliation":[{"name":"University of Manitoba; Department of Pharmacology and Therapeutics; 715 McDermot Avenue Winnipeg MB Canada R3E 3P4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheda","family":"Rabbani","sequence":"additional","affiliation":[{"name":"University of Manitoba; Department of Internal Medicine, George & Fay Yee Centre for Health Care Innovation; 753 McDermot Avenue Winnipeg Canada R3E 0T6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zarychanski","sequence":"additional","affiliation":[{"name":"University of Manitoba; Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation; Winnipeg MB Canada R3A 1R9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Abou-Setta","sequence":"additional","affiliation":[{"name":"University of Manitoba; Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation; Winnipeg MB Canada R3A 1R9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"10.1002\/14651858.CD011919.pub2-BIB0001|cit1","first-page":"S301","article-title":"Effect of resveratrol on insulin sensitivity, oxidative stress and Akt pathway in humans","volume":"53","author":"Brasny\u00f3","year":"2010","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0007114511000316","article-title":"Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients","volume":"106","author":"Brasny\u00f3","year":"2011","journal-title":"British Journal of Nutrition"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0003|cit3","unstructured":"ACTRN12613000717752 The effect of resveratrol supplementation on gut hormone secretion, gastric emptying, and blood glucose responses to meals in patients with type 2 diabetes www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=364511"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Thazhath SS Wu T Bound MJ Checklin HL Standfield S Jones KL Administration of resveratrol for 5 weeks has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial American Journal of Clinical Nutrition 2016 66 70","DOI":"10.3945\/ajcn.115.117440"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0005|cit5","unstructured":"NCT01638780 Resveratrol and type 2 diabetes clinicaltrials.gov\/show\/NCT01638780"},{"issue":"12","key":"10.1002\/14651858.CD011919.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc16-0499","article-title":"Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial","volume":"39","author":"Timmers","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0007|cit7","unstructured":"ACTRN12610000565044 Pilot clinical trial for treatment of diabetic foot ulcers with dietary nano-formulated phytochemicals www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=335696"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/816307","article-title":"Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients","volume":"2014","author":"Bashmakov","year":"2014","journal-title":"ISRN Endocrinology"},{"issue":"8","key":"10.1002\/14651858.CD011919.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7897\/2230-8407.04849","article-title":"Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial","volume":"4","author":"Bhatt","year":"2013","journal-title":"International Research Journal of Pharmacy"},{"issue":"7","key":"10.1002\/14651858.CD011919.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nutres.2012.06.003","article-title":"Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus","volume":"32","author":"Bhatt","year":"2012","journal-title":"Nutrition Research (New York, N.Y.)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0011|cit11","unstructured":"CTRI\/2011\/05\/001731 Evaluation of resveratrol as a dietary supplement in type 2 diabetes mellitus www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=2998&EncHid=&modid=&compid=%27,%272998det%27"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41387-018-0059-4","article-title":"Effects of resveratrol on bone health in type 2 diabetic patients. a double-blind randomized-controlled trial","volume":"8","author":"Bo","year":"2018","journal-title":"Nutrition and Diabetes"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.phrs.2016.08.010","article-title":"Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. a randomized, double blind, placebo-controlled trial","volume":"111","author":"Bo","year":"2016","journal-title":"Pharmacological Research"},{"issue":"5","key":"10.1002\/14651858.CD011919.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00592-017-0977-y","article-title":"Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial","volume":"54","author":"Bo","year":"2017","journal-title":"Acta Diabetologica"},{"issue":"4","key":"10.1002\/14651858.CD011919.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00592-017-1097-4","article-title":"Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation","volume":"55","author":"Bo","year":"2018","journal-title":"Acta diabetologica"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0016|cit16","unstructured":"NCT02244879 Effects of resveratrol on inflammation in type 2 diabetic patients clinicaltrials.gov\/show\/NCT02244879"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dof.2009.034.04.1360696","article-title":"Resveratrol\/SRT501. Sirtuin SIRT1 activator treatment of type 2 diabetes","volume":"34","author":"Elliott","year":"2009","journal-title":"Drugs of the Future"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nutres.2011.09.028","article-title":"Modified resveratrol longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment","volume":"31","author":"Fujitaka","year":"2011","journal-title":"Nutrition Research (New York, N.Y.)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1123\/ijsnem.2013-0045","article-title":"Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure","volume":"24","author":"Goh","year":"2014","journal-title":"International Journal of Sport Nutrition and Exercise Metabolism"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0020|cit20","unstructured":"NCT01677611 Effects of resveratrol in patients with type 2 diabetes (RED) clinicaltrials.gov\/show\/NCT01677611"},{"issue":"4","key":"10.1002\/14651858.CD011919.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1536\/ihj.16-373","article-title":"Resveratrol ameliorates arterial stiffness assessed by cardio-ankle vascular index in patients with type 2 diabetes mellitus","volume":"58","author":"Imamura","year":"2017","journal-title":"International Heart Journal"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0022|cit22","unstructured":"IRCT2015012420765N1 Impact of resveratrol supplementation on periodontal indices, antioxidant status, inflammatory markers and blood sugar in periodontal patients with type 2 diabetes mellitus en.irct.ir\/trial\/18354"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ptr.5737","article-title":"The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis","volume":"31","author":"Javid","year":"2017","journal-title":"Phytotherapy Research"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0024|cit24","first-page":"81","article-title":"Resveratrol may improve osseointegration of dental implants in type 2 diabetes mellitus patients","volume":"19","author":"Khazaei","year":"2014","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0025|cit25","unstructured":"IRCT2015080223336N2 The effect of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) inflammatory factors of patients with type 2 diabetes en.irct.ir\/trial\/19923"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.nutres.2018.03.015","article-title":"Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Khodabandehloo","year":"2018","journal-title":"Nutrition Research (New York, N.Y.)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0027|cit27","first-page":"S306","article-title":"The metabolic and anti-inflammatory effects of long-term resveratrol intake; a randomised clinical trial","volume":"57","author":"Kjaer","year":"2014","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/met.2014.0082","article-title":"Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion","volume":"12","author":"Mendez-Del Villar","year":"2014","journal-title":"Metabolic Syndrome and Related Disorders"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0029|cit29","unstructured":"IRCT201111198129N1 Effect of resveratrol in controlling blood glucose in type 2 diabetic patients en.irct.ir\/trial\/8549"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/851267","article-title":"Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients","volume":"2013","author":"Movahed","year":"2013","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0031|cit31","first-page":"A46","article-title":"Short-term resveratrol supplementation improves metabolic profile in type 2 diabetes","volume":"16","author":"Movahed","year":"2014","journal-title":"Diabetes Technology & Therapeutics"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0032|cit32","unstructured":"NCT00937222 Effects of peanut and peanut butter consumption on blood lipids and glycemic control in adults with type 2 diabetes clinicaltrials.gov\/show\/NCT00937222"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0033|cit33","unstructured":"NCT01038089 Pilot study of the effects of resveratrol on endothelial function in subjects with type 2 diabetes mellitus clinicaltrials.gov\/show\/NCT01038089"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0034|cit34","unstructured":"NCT01150955 Potential beneficial effects of resveratrol clinicaltrials.gov\/show\/NCT01150955"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0035|cit35","unstructured":"NCT01375959 Pilot study of resveratrol in older adults with impaired glucose tolerance clinicaltrials.gov\/show\/NCT01375959"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0036|cit36","unstructured":"NCT01714102 Resveratrol and the metabolic syndrome clinicaltrials.gov\/show\/NCT01714102"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0037|cit37","unstructured":"NCT01997762 Can resveratrol improve insulin sensitivity and preserve beta cell function following gestational diabetes? clinicaltrials.gov\/show\/NCT01997762"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0038|cit38","unstructured":"NCT02129595 Resveratrol and first-degree relatives of type 2 diabetic patients clinicaltrials.gov\/show\/NCT02129595"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0039|cit39","unstructured":"NCT02216552 Resveratrol for the treatment of non alcoholic fatty liver disease and insulin resistance in overweight adolescents clinicaltrials.gov\/show\/NCT02216552"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0040|cit40","unstructured":"NCT02219906 Resveratrol in metabolic syndrome clinicaltrials.gov\/show\/NCT02219906"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0041|cit41","unstructured":"NCT02565979 Long-term resveratrol and metabolism clinicaltrials.gov\/show\/NCT02565979"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0042|cit42","unstructured":"IRCT2016100716876N2 Resveratrol's effects in diabetic nephropathy https:\/\/en.irct.ir\/trial\/15666"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0043|cit43","unstructured":"NCT02704494 Resveratrol's effects in diabetic nephropathy clinicaltrials.gov\/show\/NCT02704494"},{"issue":"18","key":"10.1002\/14651858.CD011919.pub2-BIB0044|cit44","first-page":"30114","article-title":"Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial","volume":"S1262-3636","author":"Sattarinezhad","year":"2018","journal-title":"Diabetes and Metabolism"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0045|cit45","unstructured":"IRCT2015072523336N1 The effects of resveratrol on plasma and peripheral blood mononuclear cells (PBMCs) oxidative stress factors of type 2 diabetic patients https:\/\/en.irct.ir\/trial\/19922"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0046|cit46","unstructured":"Seyyedebrahimi S Khodabandehloo H Nasli Esfahani E Meshkani R Correction to: the effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial Acta Diabetologica 10.1007\/s00592-018-1160-9"},{"issue":"4","key":"10.1002\/14651858.CD011919.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00592-017-1098-3","article-title":"The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"55","author":"Seyyedebrahimi","year":"2018","journal-title":"Acta Diabetologica"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.amjcard.2012.03.030","article-title":"One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease","volume":"110","author":"Tom\u00e9-Carneiro","year":"2012","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0049|cit49","unstructured":"ACTRN12614000891628 Dose response evaluation of resveratrol supplementation on cerebrovascular function, mood and cognitive performance in type 2 diabetes mellitus (T2DM) www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=366701"},{"issue":"5","key":"10.1002\/14651858.CD011919.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.numecd.2016.03.003","article-title":"Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus","volume":"26","author":"Wong","year":"2016","journal-title":"Nutrition, Metabolism, and Cardiovascular Diseases"},{"issue":"7","key":"10.1002\/14651858.CD011919.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/nu8070425","article-title":"Acute resveratrol consumption improves neurovascular coupling capacity in adults with type 2 diabetes mellitus","volume":"8","author":"Wong","year":"2016","journal-title":"Nutrients"},{"issue":"2014","key":"10.1002\/14651858.CD011919.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.atherosclerosis.2014.05.566","article-title":"Is long-acting resveratrol effective on the residual dyslipidemia in statin-treated type 2 diabetic patients?","volume":"235","author":"Verges","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0053|cit53","unstructured":"CTRI\/2017\/04\/008384 A study to check whether addition of resveratrol is beneficial and safe in patients with diabetes, dyslipidemia and hypertension (who are already on standard therapy) www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=11073"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0054|cit54","unstructured":"IRCT201411112394N14 Effects of resveratrol on mood and cognition in patients with type 2 diabetes en.irct.ir\/trial\/2084?revision=2084"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0055|cit55","unstructured":"IRCT201601022394N19 Effect of resveratrol on serum irisin and adiponectin in patients with type 2 diabetes en.irct.ir\/trial\/2085"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0056|cit56","unstructured":"IRCT20171118037528N1 Effect of resveratrol on vascular function en.irct.ir\/trial\/27734"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0057|cit57","unstructured":"NCT01158417 Resveratrol in type2 diabetes and obesity clinicaltrials.gov\/show\/NCT01158417"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0058|cit58","unstructured":"NCT01881347 Effects of resveratrol on endothelial function in type 2 diabetes mellitus clinicaltrials.gov\/show\/NCT01881347"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0059|cit59","unstructured":"NCT02549924 Effect of administration of resveratrol on glycemic variability in individuals with type 2 diabetes mellitus clinicaltrials.gov\/show\/NCT02549924"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0060|cit60","unstructured":"SLCTR\/2018\/019 Effects of delta-tocotrienol, resveratrol and vitamin D supplementation mixture on biochemical markers in diabetic patients slctr.lk\/trials\/1304"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011919.pub2-BIB0061|cit61","first-page":"S5","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"22","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"1999","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011919.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2337\/dc08-S012","article-title":"Standards of medical care in diabetes - 2008","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011919.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1002\/mnfr.200800177","article-title":"Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers","volume":"53","author":"Almeida","year":"2009","journal-title":"Molecular Nutrition & Food Research"},{"issue":"7382","key":"10.1002\/14651858.CD011919.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature05354","article-title":"Resveratrol improves health and survival of mice on a high-calorie diet","volume":"444","author":"Baur","year":"2006","journal-title":"Nature"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.nutres.2012.06.003","article-title":"Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus","volume":"32","author":"Bhatt","year":"2012","journal-title":"Nutrition Research (New York, NY)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.maturitas.2012.05.015","article-title":"Exercise and type 2 diabetes: new prescription for an old problem","volume":"72","author":"Bird","year":"2012","journal-title":"Maturitas"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1055-9965.EPI-07-0022","article-title":"Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent","volume":"16","author":"Boocock","year":"2007","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I\u00b2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0070|cit70","unstructured":"Borenstein M Prediction intervals www.meta-analysis.com\/prediction"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2014.56.7503","article-title":"Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial","volume":"32","author":"Boutron","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0007114511000316","article-title":"Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients","volume":"106","author":"Brasnyo","year":"2011","journal-title":"British Journal of Nutrition"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1158\/0008-5472.CAN-10-2364","article-title":"Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis","volume":"70","author":"Brown","year":"2010","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1021\/jf0112973","article-title":"Plant foods and herbal sources of resveratrol","volume":"50","author":"Burns","year":"2002","journal-title":"Journal of Agricultural and Food Chemistry"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1940-6207.CAPR-09-0155","article-title":"Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study","volume":"3","author":"Chow","year":"2010","journal-title":"Cancer Prevention Research (Philadelphia, Pa.)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jrsm.1090","article-title":"Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool","volume":"5","author":"Corbett","year":"2014","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0077|cit77","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/157339911797579160","article-title":"Pharmacological management of type 2 diabetes mellitus: an update","volume":"7","author":"El-Kaissi","year":"2011","journal-title":"Current Diabetes Reviews"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.clinthera.2011.10.020","article-title":"Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review","volume":"33","author":"Germino","year":"2011","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0080|cit80","unstructured":"McMaster University (developed by Evidence Prime, Inc.) GRADEpro GDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org] 2015"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2174\/0929867043365026","article-title":"Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders","volume":"11","author":"Hansen","year":"2004","journal-title":"Current Medicinal Chemistry"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"d7202","DOI":"10.1136\/bmj.d7202","article-title":"Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses","volume":"344","author":"Hart","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mnfr.201400173","article-title":"Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus - systematic review and meta-analysis","volume":"59","author":"Hausenblas","year":"2015","journal-title":"Molecular Nutrition & Food Research"},{"issue":"11","key":"10.1002\/14651858.CD011919.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008143.pub3","article-title":"Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus","author":"Hemmingsen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series A (Statistics in Society)"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Higgins JP Altman DG G\u00f8tzsche PC J\u00fcni P Moher D Oxman AD The Cochrane collaboration's tool for assessing risk of bias in randomised trials BMJ 2011 d5928","DOI":"10.1136\/bmj.d5928"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0089|cit89","article-title":"Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011","author":"Higgins","journal-title":"Available from www.cochrane-handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0090|cit90","unstructured":"Higgins JP Altman DG Sterne JA editors(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD011919.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11531820-000000000-00000","article-title":"Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects","volume":"49","author":"Porte","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"issue":"7","key":"10.1002\/14651858.CD011919.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"6","key":"10.1002\/14651858.CD011919.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3945\/ajcn.113.082024","article-title":"Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials","volume":"99","author":"Liu","year":"2014","journal-title":"American Journal of Clinical Nutrition"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD011919.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1463-1326.2012.01653.x","article-title":"Metabolic programming of insulin action and secretion","volume":"14","author":"Martin-Gronert","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(00)02641-6","article-title":"US public health and the 21st century: diabetes mellitus","volume":"356","author":"McKinlay","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.diabres.2012.01.027","article-title":"Emerging diabetes therapies and technologies","volume":"97","author":"Moser","year":"2012","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"11","key":"10.1002\/14651858.CD011919.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2174\/092986712799945085","article-title":"Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions","volume":"19","author":"Neves","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2008.06.037","article-title":"Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats","volume":"62","author":"Palsamy","year":"2008","journal-title":"Biomedecine & Pharmacotherapie [Biomedicine & Pharmacotherapy]"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cbi.2008.11.008","article-title":"Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats","volume":"179","author":"Palsamy","year":"2009","journal-title":"Chemico-biological Interactions"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jcp.22138","article-title":"Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats","volume":"224","author":"Palsamy","year":"2010","journal-title":"Journal of Cellular Physiology"},{"issue":"8","key":"10.1002\/14651858.CD011919.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/17425247.2014.919253","article-title":"Resveratrol: review on therapeutic potential and recent advances in drug delivery","volume":"11","author":"Pangeni","year":"2014","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0107|cit107","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1021\/jf040095e","article-title":"Resveratrol, pterostilbene, and piceatannol in vaccinium berries","volume":"52","author":"Rimando","year":"2004","journal-title":"Journal of Agricultural and Food Chemistry"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0110|cit110","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0112|cit112","unstructured":"Sterne JA Egger M Moher D Boutron I editor(s) Chapter 10: Addressing reporting biases. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011919.pub2-BIB0114|cit114","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"7644","key":"10.1002\/14651858.CD011919.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011919.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12986-017-0217-z","article-title":"Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis","volume":"14","author":"Zhu","year":"2017","journal-title":"Nutrition and Metabolism"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011919.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T11:03:15Z","timestamp":1657796595000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011919.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011919.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]}}}